Bioactive peptides and proteins as alternative antiplatelet drugs |
| |
| Authors: | Kannan R.R. Rengasamy Haroon Khan Imad Ahmad Devina Lobine Fawzi Mahomoodally Shanoo Suroowan Sherif T.S. Hassan Suowen Xu Seema Patel Maria Daglia Seyed Mohammad Nabavi Shunmugiah Karutha Pandian |
| |
| Affiliation: | 1. Department of Biotechnology, Alagappa University, Karaikudi, India;2. Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, Pakistan;3. Department of Health Sciences, Faculty of Science, University of Mauritius, Réduit, Mauritius;4. Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic;5. Aab Cardiovascular Research Institute, University of Rochester, Rochester, New York;6. Bioinformatics and Medical Informatics Research Center, San Diego State University, San Diego, California;7. Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, Pavia University, Pavia, Italy;8. Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran |
| |
| Abstract: | Antiplatelet drugs reduce the risks associated with atherothrombotic events and show various applications in diverse cardiovascular diseases including myocardial infarctions. Efficacy of the current antiplatelet medicines including aspirin, clopidogrel, prasugrel and ticagrelor, and the glycoprotein IIb/IIIa antagonists, are limited due to their increased risks of bleeding, and antiplatelet drug resistance. Hence, it is important to develop new effective antiplatelet drugs, with fewer side-effects. The vast repertoire of natural peptides can be explored towards this goal. Proteins and peptides derived from snake venoms and plants represent exciting candidates for the development of novel and potent antiplatelet agents. Consequently, this review discusses multiple peptides that have displayed antiplatelet aggregation activity in preclinical drug development stages. This review also describes the antiplatelet mechanisms of the peptides, emphasizing the signaling pathways intervened by them. Also, the hurdles encountered during the development of peptides into antiplatelet drugs have been listed. Finally, hitherto unexplored peptides with the potential to prevent platelet aggregation are explored. |
| |
| Keywords: | antiplatelet effects bioactive peptides cardiovascular disease drug discovery medicinal plants pharmacokinetic profile |
|
|
